by Rachel Black | Oct 24, 2023 | Press Release
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress Read...
by Rachel Black | Oct 18, 2023 | Press Release
Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer Read...
by Jeana Newsom | Feb 23, 2023 | Press Release
Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis Read...
by dividef | May 17, 2022 | Press Release
Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting Read...
by dividef | May 10, 2022 | Press Release
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board Read...
by dividef | May 5, 2022 | Press Release
Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis Read...
Recent Comments